Oct 9 (Reuters) - AnaptysBio Inc said on Monday its experimental drug to treat a type of rare skin disease met the main goal in a late-stage study. (Reporting by Khushi Mandowara in Bengaluru; Editing by Sriraj Kalluvila)
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
23.7 USD | -2.29% | +0.85% | +10.32% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+10.32% | 662M | |
+18.12% | 124B | |
+17.54% | 111B | |
-11.46% | 23.17B | |
+5.56% | 22.94B | |
-39.94% | 17.42B | |
-9.82% | 17.42B | |
-14.92% | 16.9B | |
+2.69% | 13.71B | |
+28.04% | 11.82B |
- Stock Market
- Equities
- ANAB Stock
- News AnaptysBio, Inc.
- AnaptysBio's skin disease drug meets main goal in late-stage study